Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

As more people take GLP-1 medications for weight loss, dietitians are seeing their appointments booked out for months. Channel 2’s Lori Wilson got some advice from a Piedmont Healthcare dietitian who ...

U.S. trade policy has also heightened investor concerns over the potential impact to Novo Nordisk's key market. U.S. President Trump has threatened to unveil tariffs on pharmaceutical products in the ...

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...

Novo Nordisk says it's now cutting its annual outlook - seeing sales growth, at constant exchange rates, between 13% and 21%, vs. its previous forecast of 16% to 24%, and operating profit growth ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

The brand on Tuesday is announcing its expansion into all Walmart doors, following its latest launch: Multi-Symptom, a ...

Three years since COVID-19 abated, UnitedHealth Group, CVS Health and other insurers are still feeling the hangover, ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...